Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Ocrelizumab 600 mg vial (pa) (NDC 50242015001) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 10, 2026 , from http://ppman.hank.ai/transparency/procedure/50242015001/by-state?code_type=NDC
“Ocrelizumab 600 mg vial (pa) (NDC 50242015001) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/50242015001/by-state?code_type=NDC. Accessed
November 10, 2026 .
“Ocrelizumab 600 mg vial (pa) (NDC 50242015001) by State,” HANK Price Transparency ,
accessed November 10, 2026 ,
http://ppman.hank.ai/transparency/procedure/50242015001/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
50242015001 — Ocrelizumab 600 Mg Vial (pa)
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$34,293
National median
$17,676 – $42,134
IQR (p25 – p75)
19
hospitals filing
8
states
Walking in without insurance?
Cash / self-pay price
Cash median
$19,052
vs. negotiated
-44.4%
Hospitals reporting
46
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 50242015001 (NDC), with interquartile range
State Median p25 p75
NJ $112,113 $49,542 $203,813
IA $47,632 $39,566 $54,784
CA $41,400 $23,657 $44,357
AL $40,250 $30,026 $54,337
MI $31,757 $25,512 $39,659
OH $24,767 $15,946 $30,482
NV $21,800 $19,443 $35,351
CO $116 $113 $122